Pinna Antonio, Zinellu Angelo, Serra Rita, Boscia Giacomo, Ronchi Lorenza, Dore Stefano
Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.
Ophthalmology Unit, Azienda Ospedaliero-Universitaria di Sassari, 07100 Sassari, Italy.
Vision (Basel). 2023 Jul 28;7(3):51. doi: 10.3390/vision7030051.
We performed a systematic review and analyzed the current available data on branch retinal artery occlusion (BRAO) with simultaneous central retinal vein obstruction (CRVO), a rarely described occurrence. MEDLINE/PubMed and ISI Web of Sciences searches were performed according to MOOSE guidelines. Studies were considered eligible if they (1) described patients with simultaneous BRAO + CRVO and (2) had been published in peer-reviewed journals. We initially identified 239 records from databases. Ultimately, only 19 reports met the selection criteria. Twenty-nine patients (15 men, 14 women; mean age 43 ± 15 years) were analyzed. Seventeen (59%) patients presented vascular risk factors. Mean visual acuity at onset and final visual outcome were 20/83 and 20/45, respectively, an insignificant improvement. Vision improved in 48% of cases. A marked heterogeneity in treatment approach was found. Eight (28%) patients received no therapy, whereas for 21 (72%) a large variety of topical and/or systemic drugs was given. In the treated group, mean visual acuity at onset and final visual outcome were 20/90 and 20/44, respectively, a not statistically significant improvement. Results suggest that combined BRAO + CRVO occurs at a younger age than isolated BRAO or CRVO. At present, there is insufficient evidence to support any specific management to improve vision in simultaneous BRAO + CRVO.
我们进行了一项系统综述，并分析了目前关于视网膜分支动脉阻塞（BRAO）合并视网膜中央静脉阻塞（CRVO）这一罕见情况的可用数据。根据MOOSE指南，在MEDLINE/PubMed和ISI Web of Sciences数据库中进行了检索。如果研究（1）描述了BRAO合并CRVO的患者，且（2）发表在同行评审期刊上，则被认为符合纳入标准。我们最初从数据库中识别出239条记录。最终，只有19份报告符合入选标准。对29例患者（15例男性，14例女性；平均年龄43±15岁）进行了分析。17例（59%）患者存在血管危险因素。发病时的平均视力和最终视力结果分别为20/83和20/45，改善不显著。48%的病例视力有所改善。发现治疗方法存在显著异质性。8例（28%）患者未接受治疗，而21例（72%）患者接受了多种局部和/或全身药物治疗。在治疗组中，发病时的平均视力和最终视力结果分别为20/90和20/44，改善无统计学意义。结果表明，BRAO合并CRVO比孤立的BRAO或CRVO发病年龄更小。目前，没有足够的证据支持对BRAO合并CRVO采取任何特定的改善视力的治疗方法。
